Objective: This study concerns expression of PBK/TOPK during differentiation of HL-60 leukemic cells induced by tetradecanoyl phorbol acetate (TPA).
Methods: Wright-Giemsa staining was performed to observe morphological changes in the HL-60 cells, and flow cytometry was used to assess the cell cycle and CD11b, CD14, CD13, and CD33 expression. PBK/TOPK levels were determined by Western blot analysis.
Results: After treating HL60 cells with 5.1×10⁻⁹ mmol/L of TPA for three days, the number of nitroblue-tetrazolium-positive cells and CD11b, CD13, and CD14 expression increased, whereas the PBK/TOPK levels decreased.
Conclusions: TPA can inhibit proliferation and induce differentiation of HL60 cells of the granulocytic or monocytic lineage. PBK/TOPK expression was downregulated during this process, whereas the Pho-PBK/TOPK expression was increased.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.7314/apjcp.2012.13.5.2145 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Overexpression of PBK/TOPK relates to poor prognosis of patients with breast cancer: a retrospective analysis.
World J Surg Oncol
September 2022
The Department of Breast and Thyroid Surgery, Zhongshan Hospital Affiliated to Dalian University, No. 6, Jiefang Street, Zhongshan District, Dalian, 116001, China.
Background: PDZ-binding kinase/T-lymphokine-activated killer cell-derived protein kinase (PBK/TOPK) is a potential prognostic indicator for patients with breast cancer. The objective of the present study was to explore the relationship between PBK/TOPK expression and clinicopathological indicators as well as the survival of patients with breast cancer.
Methods: Immunohistochemical staining was used to detect the expression of PBK/TOPK in 202 cases of breast cancer tissues.
Phosphorylation of PBK/TOPK Tyr74 by JAK2 promotes Burkitt lymphoma tumor growth.
Cancer Lett
September 2022
State Key Laboratory of Cancer Biology, Department of Pathology, Xijing Hospital and School of Basic Medicine, Air Force Medical University, Xi'an, China. Electronic address:
Burkitt lymphoma (BL), which is characterized by high invasiveness, is a subgroup of non-Hodgkin lymphoma. Although BL is regarded as a highly curable disease, especially for children, some patients unfortunately still do not respond adequately. The understanding of the etiology and molecular mechanisms of BL is still limited, and targeted therapies are still lacking.
View Article and Find Full Text PDFPBK/TOPK Is a Favorable Prognostic Biomarker Correlated with Antitumor Immunity in Colon Cancers.
Biomedicines
January 2022
Department of Convergence Medicine, Asan Institute for Life Sciences, Asan Medical Center, University of Ulsan College of Medicine, Seoul 05505, Korea.
Article Synopsis
- Immune checkpoint inhibitors are effective for some colon cancer patients with specific genetic features, but there's a need for better biomarkers to identify more patients who could benefit from this treatment.
- The study found that higher levels of PBK/TOPK, a protein involved in cell regulation, were linked to improved outcomes and greater immune cell presence in colon tumors.
- Additionally, high PBK/TOPK expression correlated with more mutations in DNA repair genes and cytotoxic T-cell activity, suggesting it could be a useful biomarker for predicting responses to immunotherapy in colon cancer patients.
PBK/TOPK inhibitor OTS964 resistance is mediated by ABCB1-dependent transport function in cancer: in vitro and in vivo study.
Mol Cancer
February 2022
Department of Pharmaceutical Sciences, College of Pharmacy and Health Sciences, St. John's University, Queens, New York City, NY, 11439, USA.
Unlabelled: ABCB1 overexpression significantly desensitized both drug-selected and gene-transfected cells, which overexpress ABCB1, to OTS964 and that this drug resistance can be antagonized by verapamil, a known ABCB1 inhibitor. Consistently, a similar trend was observed in tumor-bearing mice. OTS964 stimulated ATPase activity of ABCB1 and upregulated expression levels of ABCB1, resulting in induced resistance to other ABCB1 substrate-drugs, such as paclitaxel.
View Article and Find Full Text PDFPBK/TOPK Inhibitor Suppresses the Progression of Prolactinomas.
Front Endocrinol (Lausanne)
March 2022
Department of Pharmacy, Tongren Hospital Affiliated to Wuhan University, The Third Hospital of Wuhan, Wuhan, China.
Background: Prolactinoma is the most common type of pituitary tumors, and its resultant tumor occupying and hormone disturbance greatly damage the health of patients. In this study, we investigated a protein kinase-PDZ Binding Kinase (PBK)/T-LAK Cell-Originated Protein Kinase (TOPK) as a candidate protein regulating prolactin (PRL) secretion and tumor growth of prolactinomas.
Methods: Downloaded prolactinoma transcriptome dataset from Gene Expression Omnibus (GEO) database, and screened differentially expressed genes (DEGs) between normal pituitary tissues and prolactinoma tissues.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!